Announcements Trials

Browse Landscape

Phase

Phase 1 3 Phase 2 2 Phase 4 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1 Kidney Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

Interferon-alpha 7 aldesleukin 6 Sunitinib 6 Radiotherapy 5 Nivolumab 5 Doxorubicin 5 Vincristine 4 Ipilimumab 4 Filgrastim 4 Dactinomycin 4 Chemotherapy, Adjuvant 4 Axitinib 4 cabozantinib 3 Sorafenib 3 Everolimus 3 Etoposide 3 Cyclophosphamide 3 temsirolimus 2 pembrolizumab 2 Ifosfamide 2 G250 monoclonal antibody 2 Fluorouracil 2 Carboplatin 2 Bevacizumab 2 vitespin 1 shark cartilage extract 1 pazopanib 1 lenvatinib 1 glutamic acid diethyl ester 1 cemiplimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Kidney Neoplasms × Gene Expression Profiling × Clear all

NCT01099423 2017-02-08

SURTIME

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡